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We report three consecutive patients with hypersensitivity syndrome (HSS) due to phenytoin and carbamazepine and successful
treatment with gabapentin. HSS is a rare but potentially fatal reaction to multiple drugs including several anticonvulsants.
Cross-reactivity among drugs may occur. Immediate withdrawal of the offending drug is the most important step in treatment.
Benzodiazepines acutely and, after resolution of the hepatitis, valproic acid have been successfully used for seizure control in
patients with HSS. Our cases indicate that gabapentin is also a safe anticonvulsant in HSS.
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Hypersensitivity syndrome (HSS) was first described
as serious systematic adverse reaction to phenytoin1.
Since then a limited number of additional anticonvul-
sants and other drugs including sulfonamide and allop-
urinol have also been associated with this syndrome2, 3.
Prompt recognition of HSS and withdrawal of the
offending drug is crucial in preventing a possible fatal
outcome. The use of a potentially cross-reacting anti-
convulsant drug for further seizure control in HSS is
not recommended. We present three consecutive cases
with successful treatment with gabapentin for seizure
control in the presence of HSS due to phenytoin (PHT)
and carbamazepine (CBZ).
Case Reports
Case 1
A 43-year-old african-american woman recently diag-
nosed as having complex partial and secondarily gen-
eralized seizures was started on PHT (400 mg/day)
‡ E-mail: hamer@mailer.uni-marburg.de1059–1311/99/030190 + 03 $12.00/04 weeks before admission. Four days before admis-
sion, the patient developed a pruritic rash. Fever oc-
curred and the patient experienced severe pain in both
hip joints.
On admission, the patient had a generalized skin
eruption composed of erythematous macules and 2–
3 mm follicular-based papules. Tender occipital and
submandibular lymphadenopathy and swelling of the
lower face was noted. Temperature was 39 C. Abdom-
inal, cardiac, lung and neurological examinations were
normal. Laboratory testing revealed eosinophilia and
elevated liver function tests (LFTs; Table 1).
Hypersensitivity syndrome to PHT was assumed.
Phenytoin was abruptly stopped and CBZ was started
with increasing dosages of up to 800 mg/day.
In addition, the patient received methylprednisone
180 mg/day iv, diphenhydramine 25 mg four to six
times a day and topical corticosteroids. The patient was
afebrile for the next 36 hours and felt better. However,
on day three, the temperature again rose repeatedly up
to 39.5 C and the rash worsened. Cross-reactivity be-
tween PHT and CBZ was suspected. Carbamazepine
was discontinued and gabapentin (GBP) was intro-c© 1999 BEA Trading Ltd
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Table 1: Laboratory findings in three patients with hypersensitivity syndrome.
Test Patient 1 Patient 2 Patient 3 Reference
range
PHT (serum level) 10,8 10,2 15,4 10–20 g/ml
CBZ (serum level) 4,6 7,1 3,5 8.0–12.0 g/ml
WBC 6,46 4,59 2,37 4.0–11.0 K/L
HGB 12,4 11,7 10,3 12.0–16.0 gm/dL
Neutrophils 50 47 47 40–75%
Lymphocytes 22 16 27 20–44%
Eosinophils 19,1 22 9 0–5%
Bilirubin 1,8 0,7 0,5 0.0–1.5 mg/dL
AST 997 114 904 7–46 U/L
ALT 1402 — 866 0–52 U/L
Alk phos 321 69 364 20–126 U/L
Temperature 39:5C 38:0C 38:3C
(maximal)
PHT, phenytoin; CBZ, carbamazepine; WBC, white blood cell count; HGB, hemoglobin; AST, aspartate aminotransferase; ALT, alanin
aminotransferase; Alk phos, alkaline phosphatase. Bold numbers, outside of reference range.duced. During the following three days, the general
clinical symptoms, the cutaneous eruption and the lym-
phadenopathy improved significantly.
The patient was discharged on GBP 600 mg tid po
and prednisone 60 mg/day po with a tapering dose
scale. Three days after discharge, the rash returned to
a minor extent involving mainly the trunk. No fever
or lymphadenopathy occurred. Liver function studies
were still abnormal. Treatment was not changed and the
rash slowly resolved within the next 5 days. One week
later, the patient did not have any clinical symptoms or
signs of HSS. The liver function studies became nor-
mal within 2 months after admission. The patient was
seizure free on GBP monotherapy (1800 mg/day) dur-
ing a follow-up of 18 months.
Case 2
A 52-year-old caucasian female was started on CBZ
200 mg bid due to complex partial seizures. Six weeks
later, the patient was admitted because of a pruritic
macular rash involving both arms and legs and to
a lesser extent the trunk. Abdominal, cardiac, lung
and neurological examinations were normal. No lym-
phadenopathy was noted. Temperature was 36.5 C.
Laboratory testing revealed eosinophilia and elevated
aspartate aminotransferase (Table 1).
Hypersensitivity syndrome to CBZ was suspected.
Carbamazepine was abruptly stopped and PHT was in-
troduced. She also received diphenhydramine 25 mg,
four times a day, and topical corticosteroids. The next
day, after a total dosage of 750 mg PHT, the rash be-
came more prominent. The temperature rose to 38.0 C,
and perioral swelling was noted. Cross-reactivity be-
tween CBZ and PHT was assumed. Phenytoin was dis-
continued and GBP was introduced. Over the follow-
ing 4 days, the rash and the facial swelling significantly
improved and the patient became afebrile. The facial
swelling resolved. The patient was discharged on GBP
1200 mg tid. Laboratory testing became normal withinone month. The rash did not return and the patient re-
mained on GBP monotherapy. No seizures occurred
during the follow-up of 11 months.
Case 3
A 45-year-old caucasian female was started on PHT
150 mg bid after her first complex partial seizure with
secondarily generalization. Six days later, she devel-
oped a pruritic rash. Phenytoin was stopped and CBZ
was started at a dosage of 100 mg bid. During the fol-
lowing week, the rash worsened. The patient became
febrile, felt ill, and experienced myalgias in both legs.
On admission, a maculopapular rash was noted involv-
ing the trunk and all extremities. Tender generalized
lymphadenopathy was present. Laboratory testing re-
vealed eosinophilia and elevated LFTs (Table 1).
Carbamazepine was abruptly stopped and GBP was
introduced. Tropical corticosteroids were applied. Over
the next several days, the cutaneous eruptions, lym-
phadenopathy, and myalgias disappeared. The patient
became afebrile. The patient was discharged on GBP
800 mg tid. The eosinophilia resolved and the liver
function tests became normal during the next 6 weeks.
The patient remained on GBP monotherapy and did not
experience any adverse effects. No seizures occurred
during a follow-up of 10 months.
Discussion
The cumulative evidence in these three cases indicate
that the patients’ acute illness was HSS induced by PHT
and CBZ, respectively, with possible cross-reaction be-
tween the two drugs. Hypersensitivity syndrome has
been associated with several aromatic anticonvulsants
including PHT, CBZ, phenobarbital (PB), primidone
(PRM), felbamate (FBM) and lamotrigine (LTG)2–4.
Valproic acid (VPA) is often viewed as safer in respect
to cutaneous reactions5 although there have been oc-
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HSS, as compared to aromatic anticonvulsants6. To the
best of our knowledge, HSS has not yet been described
for benzodiazepines, GBP, vigabatrin (VGB), and top-
iramate (TPM).
The population risk for hypersensitivity syndrome
ranges between 1:1000 to 1:10 000 exposures, equally
for all associated anticonvulsants4. The onset of HSS
usually occurs within one week to three months after
initiation of drug treatment4, 7. Hypersensitivity syn-
drome is a clinical diagnosis. The hallmarks are fever,
rash, tender lymphadenopathy, eosinophilia and hep-
atitis with abnormal LFTs.
Hypersensitivity syndrome appears to be idiosyn-
cratic7. Its exact pathogenesis is unknown. The molecu-
lar structure of PHT, CBZ and PB contains an aromatic
ring compound which is metabolized to reactive arene
oxides. Due to a genetically determined inefficient en-
zymatic detoxification, these intermediates may accu-
mulate and trigger a systemic auto-immune response2.
Clinical cross-reactivity between PHT, CBZ, PRM, PB
as well as oxcarbazepine (OCBZ) has been reported4, 8.
In vitro analyses using lymphocyte toxicity assays sug-
gest up to 80% cross-reactivity between these drugs2.
Immediate withdrawal of the drug is the first and
most important step in treatment of HSS. In severe
cases, systemic corticosteroids and antihistamines may
be given4. Usually, the rash also responds well to topi-
cal steroids, and wet wraps. The majority of the patients
completely recover within days or a few weeks7. How-
ever, the clinical syndrome of hypersensitivity may
fluctuate or even relapse with fever and rash for weeks
after discontinuation of the offending drug2, 7. Note, in
patient 1, the rash returned for a brief period of time
and resolved without change in treatment.
The use of PHT, PB, PRM, CBZ, OCBZ for fur-
ther seizure control in HSS is not recommended since
potential cross-reactivity can blur or even worsen the
clinical course. Felbamate and LTG may also cause
HSS and other idiosyncratic reactions and need to be
initiated at low dosages and escalated slowly3. There-
fore, they may not be the anticonvulsant drugs of choice
in the presence of HSS. The experience with VGB in
Europe is still limited3 and it is not yet approved in
the USA, so that its possible indication in HSS is un-
clear.
A benzodiazepine can be substituted for acute seizure
control4. Valproic acid has also successfully been used
in the treatment of these patients but probably should
not be given during the acute or convalescent phase
because of its hepatic metabolism4, 5.The presented cases demonstrate that GBP may be
given as anticonvulsant drug in the acute phase of HSS.
It can be quickly loaded orally and is not metabolized
by the liver, but excreted, unchanged, by the kidney9.
It has not been associated with HSS or other severe id-
iosyncratic reactions and has a low potential for other
serious adverse effects9. Gabapentin is approved as ad-
junctive drug in the treatment of partial seizures and
secondarily generalized tonic–clonic seizures, and has
also been shown to be effective as monotherapy10.
Therefore, GBP seems to be a good alternative drug
for seizure control in the presence of HSS to other an-
ticonvulsant drugs.
In conclusion, hypersensitivity syndrome is a rare
but serious multiorgan syndrome with a genetic com-
ponent caused by several anticonvulsant drugs. Imme-
diate withdrawal of the offending drug is the main
step to complete recovery. Gabapentin may be the an-
ticonvulsant drug of choice in this situation providing
the patient has partial and/or secondarily generalized
seizures.
